eFFECTOR Therapeutics EBIT

eFFECTOR Therapeutics (EFTR) currently reports a EBIT of $-320K as of March 2026. That compares with $-33M in the prior-year period — up 99.0% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore eFFECTOR Therapeutics's EBIT history and peer comparisons.

eFFECTOR Therapeutics's EBIT increased from $-33M to $-320K — a 99.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

eFFECTOR Therapeutics's EBIT of $-320K is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

eFFECTOR Therapeutics reported $-320K in EBIT as of March 2026. That compares with $-33M in the prior-year period — up 99.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-320K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for eFFECTOR Therapeutics, and consider following EFTR for alerts when major investors trade the stock.